Keywords: اورولیموس; Drug-induced lung injury; Everolimus; Mammalian target of rapamycin (mTOR); Lactate dehydrogenase; Krebs von den Lungen-6; Ground-glass opacity;
مقالات ISI اورولیموس (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اورولیموس; Cost Effectiveness; Everolimus; Immunotherapy; Programmed death 1 receptor; Renal cell carcinoma;
Keywords: اورولیموس; Primary hepatic angiosarcoma; Liver transplantation; Everolimus;
Keywords: اورولیموس; Everolimus; Medical treatment; Surgery; Peptide receptor radionuclide therapy; Somatostatin receptor ligands; Sunitinib; Telotristat etiprate; Theranostics;
Keywords: اورولیموس; Renal cell carcinoma; Overcoming drug resistance; Macrophage modulation; Everolimus; Tumor core penetration; Nano-therapy; Tumor hypoxia targeting; Carbonic anhydrase IX;
Keywords: اورولیموس; Chromophobe; Everolimus; Lenvatinib; Non-clear-cell renal cell carcinoma; Treatment;
Keywords: اورولیموس; tuberous sclerosis complex; mTOR inhibitors; SEGA; everolimus; hydrocephalus; treatment;
Keywords: اورولیموس; Genomic biomarker; Kidney cancer; Targeted therapy; Everolimus; Sunitinib; Tumor suppressor gene; PBRM1; SETD2; BAP1; KDM5C;
Keywords: اورولیموس; A2309 trial; ANZDATA; cancer; cyclosporine; epidemiology; everolimus;
Keywords: اورولیموس; Non-clear cell renal cell carcinoma; Papillary; Chromophobe; Sunitinib; Everolimus; Systematic review;
Keywords: اورولیموس; AE; Adverse Event; AUC; Area Under the Curve; BIC; Bayesian information criterion; BP; Bisphosphonate; C0; Trough level; CT; Adjuvant chemotherapy; EVR; Everolimus; GEE; generalized estimating equation; HT; Adjuvant hormonotherapy; MDRD; Modification of D
Keywords: اورولیموس; PI3K; phosphatidylinositol 3-kinase; PIK3CA; PI3K catalytic subunit alpha; Akt; protein kinase B; mTOR; mammalian target of the rapamycin pathway; GPCRs; G-protein-coupled-receptors; PTEN; phosphatase and tensin homolog; GAP; GTPase-activating protein; pY
Keywords: اورولیموس; Chemoradiation; Everolimus; Maintenance; Metastasis; Target therapy;
Keywords: اورولیموس; Drug coated balloon; Drug-eluting stent; Everolimus; Porcine coronary artery;
Keywords: اورولیموس; Therapeutic drug monitoring; Immunosuppressant; Liquid chromatography; Mass spectrometry; Cyclosporine A; Tacrolimus; Sirolimus; Everolimus;
Keywords: اورولیموس; Acute rejection; Everolimus; Liver transplantation; mTORi;
Keywords: اورولیموس; Endocrine resistance; Breast cancer; Fulvestrant; Palbociclib; Everolimus; Mechanism of resistance;
Keywords: اورولیموس; Hepatocellular cancer; Target therapies; Second line; Everolimus; Ramucirumab;
Keywords: اورولیموس; Breast cancer; Metastatic; Hormone receptor; Everolimus; Endocrine therapy
Keywords: اورولیموس; drug-eluting stent(s); dual antiplatelet therapy; everolimus; stent thrombosisBMS, bare-metal stent(s); CI, confidence interval; DAPT, dual antiplatelet therapy; DES, drug-eluting stent(s); EES, everolimus-eluting stent(s); HR, hazard ratio; MACCE, major
Keywords: اورولیموس; Neuroendocrine tumors; Pancreatic neuroendocrine tumors; Carcinoid tumors; Octreotide; Lanreotide; Sunitinib; Everolimus;
Keywords: اورولیموس; Pancreatic neuroendocrine tumor; Somatostatin analogue; mTOR; Everolimus; Sunitinib; Temozolomide;
Keywords: اورولیموس; Immunosuppressants; Therapeutic drug monitoring; Transplantation; Ciclosporin; Tacrolimus; Everolimus; Sirolimus; Mycophenolic acid; Thiopurines; Pharmacokinetic; AcMPAG; acyl glucuronide of mycophenolic acid; CsA; ciclosporin A; EVR; everolimus; IATDMCT;
Keywords: اورولیموس; Calcineurin inhibitor withdrawal; Mammalian target of rapamycin inhibitors; Everolimus; Renal transplantation; Long-term follow-up;
Keywords: اورولیموس; AKT inhibitor; autoimmune adverse effects; autoimmune dermopathies; B-RAF; dabrafenib; dermatitis; dual inhibitor; dysgeusia; everolimus; hair loss; hedgehog signaling pathway; immunotherapy; immune-related toxicities; ipilimumab; keratoacanthoma; keratos
Keywords: اورولیموس; Pirfenidone (Pub Chem CID: 40632); Rapamycin (Pub Chem CID: 5284616); Zotarolimus (Pub Chem CID: 23375907); Everolimus (Pub Chem CID: 6442177); Paclitaxel (Pub Chem CID: 441276); Pirfenidone; Zotarolimus; Everolimus; Rapamycin;
Keywords: اورولیموس; Everolimus; mTOR inhibitor; Targeted therapy; Temsirolimus; Treatment-naive
Keywords: اورولیموس; Everolimus; Solid dispersion; Oral absorption; Stability; Solvent wetting technique;
Keywords: اورولیموس; Renal cell carcinoma; Sorafenib; Pazopanib; Everolimus; Sunitinib; Bevacizumab; Axitinib; Antiangiogenic therapy; Treatment algorithm;
Keywords: اورولیموس; Insuficiencia renal; Trasplante hepático; Everolimus; Inhibidores de la mammalian target of rapamycin; Renal failure; Liver transplantation; Everolimus; Mammalian target of rapamycin inhibitors;
Keywords: اورولیموس; Renal cell carcinoma; Sequential therapy; Survival; Sunitinib; Sorafenib; Everolimus; Bevacizumab; Axitinib; Temsirolimus; Third-line;
Keywords: اورولیموس; Breast cancer; Adverse events; Trastuzumab; Pertuzumab; Lapatinib; Bevacizumab; Trastuzumab-emtansine; Everolimus; ABC; advanced breast cancer; QoL; quality of life; AE; adverse event; HER2; human epidermal growth factor receptor type 2; LVEF; left ventri
Keywords: اورولیموس; Drug delivery; Everolimus; Heart; Self-assembly; Stent; Thiol;
Keywords: اورولیموس; Brentuximab vedotin Pembrolizumab; Nivolumab; Everolimus; Hodgkin lymphoma
Keywords: اورولیموس; Tuberous sclerosis; Everolimus; Vigabatrin; Early treatment; Epilepsy; Neurodevelopmental disorders
Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease
Keywords: اورولیموس; Intrathecal administration; Everolimus; Mammalian target of rapamycin; Alzheimer's disease; Depression; Learning and memory; 3â¯Ãâ¯Tg-AD mice;
Dramatic relapse of seizures after everolimus withdrawal
Keywords: اورولیموس; Everolimus; Subependymal giant cell astrocytoma; SEGA; Tuberous sclerosis complex; Epilepsy; mTOR inhibitors;
Aggressive neuroendocrine tumor of the ovary with multiple metastases treated with everolimus: A case report
Keywords: اورولیموس; Carcinoid; Everolimus; Multiple metastases; Neuroendocrine tumor; Ovary; NETs; neuroendocrine tumors; FIGO; International Federation of Gynecology and Obstetrics; mTOR; mammalian target of rapamycin; MRI; magnetic resonance imaging; CT; computed tomograph
Efficacy and safety of everolimus in patients younger than 12â¯months with congenital subependymal giant cell astrocytoma
Keywords: اورولیموس; ACTH; adrenocorticotropic hormone; CRM; cardiac rhabdomyoma; CT; computed tomography; EVL; everolimus; HHV7; human herpes virus 7; MRI; magnetic resonance imaging; mTOR; mammalian target of rapamycin; SEGA; subependymal giant cell astrocytoma; TAND; TSC-a
Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: A meta-analysis
Keywords: اورولیموس; Mammalian target of rapamycin inhibitors; Sirolimus; Everolimus; Heart transplant; Coronary allograft vasculopathy;
Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity
Keywords: اورولیموس; mTOR inhibitor; Liver; Transplantation; Regulatory T-cells; Calcineurin inhibitor.; CD; Cluster of differentiation; CNI; Calcineurin Inhibitor; EVR; Everolimus; HCC; Hepatocellular carcinoma; MMF; Mycophenolate Mofetil; PBMC; Peripheral Blood Mononuclear
Role for primary immunosuppression with everolimus after pulmonary transplantation
Keywords: اورولیموس; Lung transplantation; Everolimus; Cyclosporine A; Primary immunosuppression;
Role of WNT/β-Catenin Pathway as Potential Prognostic and Predictive Factors in Renal Cell Cancer Patients Treated With Everolimus in the Second and Subsequent Lines
Keywords: اورولیموس; β-Catenin; E-cadherin; Everolimus; RCC; WNT;
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Keywords: اورولیموس; Advanced breast cancer; Metastatic; Chemotherapy; Antihormone therapy; Aromatase inhibitor; Fulvestrant; Tamoxifen; Everolimus; Therapy/treatment sequence;
Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial
Keywords: اورولیموس; Advanced breast cancer; Endocrine therapy; Everolimus; Hormone receptor-positive; Letrozole;
Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin
Keywords: اورولیموس; Navitoclax (ABT-263); Everolimus; Survivin; Breast cancer;
Liver Angiomyolipomas in Tuberous Sclerosis Complex-Their Incidence and Course
Keywords: اورولیموس; tuberous sclerosis; mTOR; angiomyolipoma; mTOR inhibitors; everolimus; TSC1; TSC2;
Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting
Keywords: اورولیموس; Everolimus; Dried blood spot testing; Analytical method; Oncology; UPLC-MS/MS; Hematocrit;
Everolimus-based combination therapies for HR+, HER2â metastatic breast cancer
Keywords: اورولیموس; Everolimus; Metastatic breast cancer; Endocrine therapy; Hormone receptor-positive;
Influence of immunosuppressive drugs on the CD30 molecule in kidney transplanted patients
Keywords: اورولیموس; ADAM; a disintegrin and metallopeptidase; CNI; calcineurin inhibitor; DGF; delayed graft function; DSA; donor-specific antibodyies; eGFR; estimated glomerular filtration rate; EVR; everolimus; CI; confidence interval; IF/TA; interstitial fibrosis/tubular